The present study addresses this critical knowledge gap by evaluating serum levels of three key inflammatory markers (IL-6, TNF-α, and hsCRP) in a well-characterized cohort of patients with MASLD and systematically analyzing their correlations with: (1) disease severity assessed through five validated non-invasive indices (APRI, FIB-4, NAFLD fibrosis score, FAST score, and transient elastography with controlled attenuation parameter), and (2) key metabolic parameters, including anthropometric indices, glycemic control, and comprehensive lipid profiling. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.